ASCO's Government Relations Committee establishes policy priorities on an annual basis. These priorities are updated as needed to reflect emerging issues. 

GOAL 1: Pursue access to high quality, affordable care for every patient with cancer

  • Advocate for policies at the federal and state level to ensure that all cancer patients and survivors have access to adequate and affordable health insurance.
  • Advocate policies that require Medicare, Medicaid, Health Insurance Exchanges and commercial health plans to provide coverage for the full range of services needed to prevent, diagnose and treat cancer.
  • Advocate policies that protect cancer patients from high cost-sharing requirements that target anti-cancer medicines and supportive care therapies.
  • Ensure continuation of clinical trials coverage provisions and extend these to all health plans for all phases of clinical trials

GOAL 2: Advance evidence-based policies and delivery system reform that supports oncology providers in their delivery of high quality, high value cancer care 

  • Support continuity of patient access to anti-cancer therapies by maintaining the current ASP system until an adequate value-based replacement is tested and adopted.
  • Advocate for payment models that include payment supporting the full range of services needed by patients with cancer, including multidisciplinary care coordination, patient counseling and navigation, palliative care, tobacco cessation, survivorship care, and end of life care.
  • Pursue qualification of PCOP as an alternative payment model under Medicare Access and CHIP Reauthorization Act (MACRA).  Advocate for the testing and adoption of a variety of oncology specific Alternative Payment Models (APMs) and models that contain components that are compatible with the field of oncology.
  • Ensure MACRA is implemented in a way that sustains an effective, efficient and healthy practice environment, for example by establishing measures that ensure fair and accurate provider performance assessment and removing Part B drugs from resource allocation performance assessment, and allowing practices to use QOPI to fulfill federal performance reporting requirements.
  • Promote policies that eliminate the obligation for practices to participate in multiple pathway and reporting systems.
  • Promote the exchange of health care information to advance treatment and support delivery of high value, high quality care by removing barriers to, advancing the awareness of and increasing support for learning systems like ASCO’s CancerLinQ and by pursuing regulatory and legislative remedies to information blocking.

GOAL 3: Advocate for policies that support a robust federally funded cancer research, prevention, drug development and clinical trials system. 

  • Advocate for robust and sustainable increases in federal budgets for the National Institutes of Health (NIH).
  • Advocate for funding of more inclusive and robust clinical trials, specifically including minorities and the underserved.
  • Support the recommendations of the Blue Ribbon Panel of the Beau Biden Cancer Moonshot to apply cancer research funding to the National Cancer Institute directly.
  • Advocate for increased funding and Congressional support for Food and Drug Administration’s (FDA) programs to review safety and efficacy of therapies and diagnostics, drug shortage prevention programs, and regulatory authority of tobacco products.
  • Advocate policies that support a sustainable clinical trials system, including standardization and streamlining of administrative and regulatory processes associated with clinical trials, as well as reimbursement for the additional time and effort required for clinical investigators to involve patients in clinical trials.
  • Advocate for Congress to require the CDC, other collaborating institutions, and states in developing comprehensive cancer control plans that include consideration of survivorship care, and promoting the implementation, evaluation, and refinement of existing cancer control plans.